Vaccine gets market approval


BEIJING: China’s National Medical Products Administration (NMPA) has granted conditional market approval to CoronaVac, an inactivated Covid-19 vaccine developed by Sinovac Biotech, the company said.The Sinovac vaccine, produced by the Beijing-based Sinovac Life Sciences Co Ltd, affiliated with Sinovac Biotech, was approved for emergency use in China last June.

It started being used for emergency inoculation among special groups in China from July last year.

Get 30% off with our ads free Premium Plan!

Monthly Plan

RM13.90/month
RM9.73 only

Billed as RM9.73 for the 1st month then RM13.90 thereafters.

Annual Plan

RM12.33/month
RM8.63/month

Billed as RM103.60 for the 1st year then RM148 thereafters.

1 month

Free Trial

For new subscribers only


Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
   

Next In Aseanplus News

Philippine VP Sara Duterte’s US$10mil snack-name scandal: a recipe for impeachment?
Alleged burglars entered Holland Road home via construction site
Cambodia court jails opposition party leader Sun Chanthy
New Bang Yai–Kanchanaburi motorway opens for free trial until Jan 2
Comedian Mark Lee’s comedy 'Number 1's sequel to be released over CNY
Lao, Thai governments vow to strengthen ties over war on drugs
Bursa Malaysia seeks feedback on depository rules for electronic CDS statements
Lord Of The Rings musical to make Asian debut in Singapore in August 2025
MACC to focus on grand corruption battle, national asset recovery in 2025
South Korea to review visa-free pilot project for Chinese group tourists

Others Also Read